Anti-high mobility group box-1 antibody therapy for traumatic brain injury

Yu Okuma, Keyue Liu, Hidenori Wake, Jiyong Zhang, Tomoko Maruo, Isao Date, Tadashi Yoshino, Aiji Ohtsuka, Naoki Otani, Satoshi Tomura, Katsuji Shima, Yasuhiko Yamamoto, Hiroshi Yamamoto, Hideo K. Takahashi, Shuji Mori, Masahiro Nishibori

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Objective: High mobility group box-1 (HMGB1) plays an important role in triggering inflammatory responses in many types of diseases. In this study, we examined the involvement of HMGB1 in traumatic brain injury (TBI) and evaluated the ability of intravenously administered neutralizing anti-HMGB1 monoclonal antibody (mAb) to attenuate brain injury. Methods: Traumatic brain injury was induced in rats or mice by fluid percussion. Anti-HMGB1 mAb or control mAb was administered intravenously after TBI. Results: Anti-HMGB1 mAb remarkably inhibited fluid percussion-induced brain edema in rats, as detected by T2-weighted magnetic resonance imaging; this was associated with inhibition of HMGB1 translocation, protection of blood-brain barrier (BBB) integrity, suppression of inflammatory molecule expression, and improvement of motor function. In contrast, intravenous injection of recombinant HMGB1 dose-dependently produced the opposite effects. Experiments using receptor for advanced glycation end product (RAGE)-/-, toll-like receptor-4 (TLR4)-/-, and TLR2-/- mice suggested the involvement of RAGE as the predominant receptor for HMGB1. Interpretation: Anti-HMGB1 mAb may provide a novel and effective therapy for TBI by protecting against BBB disruption and reducing the inflammatory responses induced by HMGB1. ANN NEUROL 2012;72:373-384

Original languageEnglish
Pages (from-to)373-384
Number of pages12
JournalAnnals of Neurology
Volume72
Issue number3
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Monoclonal Antibodies
Antibodies
Percussion
Blood-Brain Barrier
Therapeutics
Brain Edema
Intravenous Injections
Brain Injuries
Magnetic Resonance Imaging
Traumatic Brain Injury
Advanced Glycosylation End Product-Specific Receptor

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Anti-high mobility group box-1 antibody therapy for traumatic brain injury. / Okuma, Yu; Liu, Keyue; Wake, Hidenori; Zhang, Jiyong; Maruo, Tomoko; Date, Isao; Yoshino, Tadashi; Ohtsuka, Aiji; Otani, Naoki; Tomura, Satoshi; Shima, Katsuji; Yamamoto, Yasuhiko; Yamamoto, Hiroshi; Takahashi, Hideo K.; Mori, Shuji; Nishibori, Masahiro.

In: Annals of Neurology, Vol. 72, No. 3, 09.2012, p. 373-384.

Research output: Contribution to journalArticle

Okuma, Y, Liu, K, Wake, H, Zhang, J, Maruo, T, Date, I, Yoshino, T, Ohtsuka, A, Otani, N, Tomura, S, Shima, K, Yamamoto, Y, Yamamoto, H, Takahashi, HK, Mori, S & Nishibori, M 2012, 'Anti-high mobility group box-1 antibody therapy for traumatic brain injury', Annals of Neurology, vol. 72, no. 3, pp. 373-384. https://doi.org/10.1002/ana.23602
Okuma, Yu ; Liu, Keyue ; Wake, Hidenori ; Zhang, Jiyong ; Maruo, Tomoko ; Date, Isao ; Yoshino, Tadashi ; Ohtsuka, Aiji ; Otani, Naoki ; Tomura, Satoshi ; Shima, Katsuji ; Yamamoto, Yasuhiko ; Yamamoto, Hiroshi ; Takahashi, Hideo K. ; Mori, Shuji ; Nishibori, Masahiro. / Anti-high mobility group box-1 antibody therapy for traumatic brain injury. In: Annals of Neurology. 2012 ; Vol. 72, No. 3. pp. 373-384.
@article{5c16480986b4422c82c65b3eb0538a6e,
title = "Anti-high mobility group box-1 antibody therapy for traumatic brain injury",
abstract = "Objective: High mobility group box-1 (HMGB1) plays an important role in triggering inflammatory responses in many types of diseases. In this study, we examined the involvement of HMGB1 in traumatic brain injury (TBI) and evaluated the ability of intravenously administered neutralizing anti-HMGB1 monoclonal antibody (mAb) to attenuate brain injury. Methods: Traumatic brain injury was induced in rats or mice by fluid percussion. Anti-HMGB1 mAb or control mAb was administered intravenously after TBI. Results: Anti-HMGB1 mAb remarkably inhibited fluid percussion-induced brain edema in rats, as detected by T2-weighted magnetic resonance imaging; this was associated with inhibition of HMGB1 translocation, protection of blood-brain barrier (BBB) integrity, suppression of inflammatory molecule expression, and improvement of motor function. In contrast, intravenous injection of recombinant HMGB1 dose-dependently produced the opposite effects. Experiments using receptor for advanced glycation end product (RAGE)-/-, toll-like receptor-4 (TLR4)-/-, and TLR2-/- mice suggested the involvement of RAGE as the predominant receptor for HMGB1. Interpretation: Anti-HMGB1 mAb may provide a novel and effective therapy for TBI by protecting against BBB disruption and reducing the inflammatory responses induced by HMGB1. ANN NEUROL 2012;72:373-384",
author = "Yu Okuma and Keyue Liu and Hidenori Wake and Jiyong Zhang and Tomoko Maruo and Isao Date and Tadashi Yoshino and Aiji Ohtsuka and Naoki Otani and Satoshi Tomura and Katsuji Shima and Yasuhiko Yamamoto and Hiroshi Yamamoto and Takahashi, {Hideo K.} and Shuji Mori and Masahiro Nishibori",
year = "2012",
month = "9",
doi = "10.1002/ana.23602",
language = "English",
volume = "72",
pages = "373--384",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Anti-high mobility group box-1 antibody therapy for traumatic brain injury

AU - Okuma, Yu

AU - Liu, Keyue

AU - Wake, Hidenori

AU - Zhang, Jiyong

AU - Maruo, Tomoko

AU - Date, Isao

AU - Yoshino, Tadashi

AU - Ohtsuka, Aiji

AU - Otani, Naoki

AU - Tomura, Satoshi

AU - Shima, Katsuji

AU - Yamamoto, Yasuhiko

AU - Yamamoto, Hiroshi

AU - Takahashi, Hideo K.

AU - Mori, Shuji

AU - Nishibori, Masahiro

PY - 2012/9

Y1 - 2012/9

N2 - Objective: High mobility group box-1 (HMGB1) plays an important role in triggering inflammatory responses in many types of diseases. In this study, we examined the involvement of HMGB1 in traumatic brain injury (TBI) and evaluated the ability of intravenously administered neutralizing anti-HMGB1 monoclonal antibody (mAb) to attenuate brain injury. Methods: Traumatic brain injury was induced in rats or mice by fluid percussion. Anti-HMGB1 mAb or control mAb was administered intravenously after TBI. Results: Anti-HMGB1 mAb remarkably inhibited fluid percussion-induced brain edema in rats, as detected by T2-weighted magnetic resonance imaging; this was associated with inhibition of HMGB1 translocation, protection of blood-brain barrier (BBB) integrity, suppression of inflammatory molecule expression, and improvement of motor function. In contrast, intravenous injection of recombinant HMGB1 dose-dependently produced the opposite effects. Experiments using receptor for advanced glycation end product (RAGE)-/-, toll-like receptor-4 (TLR4)-/-, and TLR2-/- mice suggested the involvement of RAGE as the predominant receptor for HMGB1. Interpretation: Anti-HMGB1 mAb may provide a novel and effective therapy for TBI by protecting against BBB disruption and reducing the inflammatory responses induced by HMGB1. ANN NEUROL 2012;72:373-384

AB - Objective: High mobility group box-1 (HMGB1) plays an important role in triggering inflammatory responses in many types of diseases. In this study, we examined the involvement of HMGB1 in traumatic brain injury (TBI) and evaluated the ability of intravenously administered neutralizing anti-HMGB1 monoclonal antibody (mAb) to attenuate brain injury. Methods: Traumatic brain injury was induced in rats or mice by fluid percussion. Anti-HMGB1 mAb or control mAb was administered intravenously after TBI. Results: Anti-HMGB1 mAb remarkably inhibited fluid percussion-induced brain edema in rats, as detected by T2-weighted magnetic resonance imaging; this was associated with inhibition of HMGB1 translocation, protection of blood-brain barrier (BBB) integrity, suppression of inflammatory molecule expression, and improvement of motor function. In contrast, intravenous injection of recombinant HMGB1 dose-dependently produced the opposite effects. Experiments using receptor for advanced glycation end product (RAGE)-/-, toll-like receptor-4 (TLR4)-/-, and TLR2-/- mice suggested the involvement of RAGE as the predominant receptor for HMGB1. Interpretation: Anti-HMGB1 mAb may provide a novel and effective therapy for TBI by protecting against BBB disruption and reducing the inflammatory responses induced by HMGB1. ANN NEUROL 2012;72:373-384

UR - http://www.scopus.com/inward/record.url?scp=84867101159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867101159&partnerID=8YFLogxK

U2 - 10.1002/ana.23602

DO - 10.1002/ana.23602

M3 - Article

C2 - 22915134

AN - SCOPUS:84867101159

VL - 72

SP - 373

EP - 384

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 3

ER -